OR WAIT null SECS
Following a recent expansion at its Cambridge, MA, facility, the company now houses a new suite of cellular analysis platforms that enhance its exploratory capabilities into oncology, neuroscience, and rare diseases.
The recent addition in September 2020 of a state-of-the-art suite of cellular analysis platforms at its Discovery Biology facility in Cambridge, MA, gives India-based Sai Life Sciences, a discovery, contract development, and manufacturing solutions company, expanded screening capabilities. The Cambridge facility now includes the Opera Phenix high content screening platform, FACSCelesta flow cytometer, and FACSMelody flow sorter, technologies that enable the company to better serve start-up and biotech companies in the region, especially in projects exploring novel biology in oncology, neuroscience, and rare diseases.
Over the past year, Sai has delivered a range of projects, including genetic and pharmacological target validation studies and reagent validation. It has also developed a variety of assays, such as cellular target engagement assays and in-vitro biomarker assessments.
The company’s 8500-ft2 lab in Cambridge creates opportunities for local biotechs to have frequent face-to-face collaboration with Sai scientists and to accelerate the pace of externalized research by reducing cycle-times. The lab’s focus on exploratory research allows for complex biology projects that necessitate more fluid experimental design with real-time decision making.
“We are committed to helping our clients successfully advance their internal discovery portfolios and are investing considerable resources to provide world-class service in the Boston area. These new capability additions are just the latest in our strategic growth plan with significant additional capabilities coming soon,” said Krishna Kanumuri, CEO and managing director of Sai Life Sciences, in a Sept. 10, 2020 press release.
Source: Sai Life Sciences